

# Phase 1 Clinical Development of Cerium Oxide-Based Nanozyme CX213 for the Treatment of Subarachnoid Hemorrhage as an Orphan Drug

Cenyx Biotech Inc.



NEUROLOGY	Phase 1
Product Type	Others-Synth.
Indication	Subarachnoid Hemorrhage
Target	Reactive Oxygen Species (ROS)
MoA(Mechanism of Action)	First-in-class nanozyme therapeutic that rapidly scavenges ROS through a self-regenerating redox mechanism, effectively halting inflammation and tissue damage at the earliest stage
Competitiveness	CX213 uniquely addresses a critical unmet need as the first and only drug targeting the hyperacute phase of subarachnoid hemorrhage, where no approved therapies currently exist. Its robust, self-renewing ROS-scavenging mechanism sets it apart from conventional antioxidants and repurposed agents, enabling superior efficacy in severe, treatment-resistant cases.
Development Stage	Phase 1
Route of Administration	Intravenous Injection (IV)

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*